Clinical Trial Update: CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CD30-directed CAR-T therapy (CART30) for relapsed/refractory CD30-positive lymphomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD30-directed CAR-T (CART30) Therapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: RECRUITING